Potential Role of Donor-Derived Cell Free DNA as a New Biomarker in Cardiac Allograft Vasculopathy (FreeDNA-CAV)

There is an unmet need for a noninvasive biomarker for cardiac allograft vasculopathy (CAV), that could obviate the need to perform surveillance coronary angiograms in HT recipients. Donor-derived cell free DNA (ddcf-DNA) has shown a good ability to rule out cellular rejection, but its performance as a biomarker for CAV has not been tested.We sought to evaluate the performance of ddcf-DNA as a biomarker of CAV in a cohort of patients undergoing routine coronariography.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (560) Source Type: research